Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
foresiGHt trial of once-weekly lonapegsomatropin in adults with growth hormone deficiency
2020-000929-42Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Oct 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lonapegsomatropin in adult onset growth hormone deficiency (AGHD) (3 arms), sponsored by Ascendis Pharma. Primary endpoint: Change from baseline in trunk percent fat at Week 38. Started Oct 2020; status: completed.
02
Drugs
lonapegsomatropin
03
Conditions
adult onset growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on 2020-000929-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000929-42.